OBJECTIVES: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. METHODS: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). RESULTS: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. CONCLUSION: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.
OBJECTIVES:Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. METHODS:PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). RESULTS: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. CONCLUSION: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.
Authors: Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald Journal: Gynecol Oncol Date: 2006-10-24 Impact factor: 5.482
Authors: Hiu Wing Cheung; Glenn S Cowley; Barbara A Weir; Jesse S Boehm; Scott Rusin; Justine A Scott; Alexandra East; Levi D Ali; Patrick H Lizotte; Terence C Wong; Guozhi Jiang; Jessica Hsiao; Craig H Mermel; Gad Getz; Jordi Barretina; Shuba Gopal; Pablo Tamayo; Joshua Gould; Aviad Tsherniak; Nicolas Stransky; Biao Luo; Yin Ren; Ronny Drapkin; Sangeeta N Bhatia; Jill P Mesirov; Levi A Garraway; Matthew Meyerson; Eric S Lander; David E Root; William C Hahn Journal: Proc Natl Acad Sci U S A Date: 2011-07-11 Impact factor: 11.205
Authors: Anna R Laury; Ruth Perets; Huiying Piao; Jeffrey F Krane; Justine A Barletta; Christopher French; Lucian R Chirieac; Rosina Lis; Massimo Loda; Jason L Hornick; Ronny Drapkin; Michelle S Hirsch Journal: Am J Surg Pathol Date: 2011-06 Impact factor: 6.394
Authors: Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; Andreas Du Bois Journal: Gynecol Oncol Date: 2007-03-29 Impact factor: 5.482
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi Journal: Nat Med Date: 1998-07 Impact factor: 53.440
Authors: Martin Köbel; Steve E Kalloger; Niki Boyd; Steven McKinney; Erika Mehl; Chana Palmer; Samuel Leung; Nathan J Bowen; Diana N Ionescu; Ashish Rajput; Leah M Prentice; Dianne Miller; Jennifer Santos; Kenneth Swenerton; C Blake Gilks; David Huntsman Journal: PLoS Med Date: 2008-12-02 Impact factor: 11.069
Authors: Emily K Adler; Rosario I Corona; Janet M Lee; Norma Rodriguez-Malave; Paulette Mhawech-Fauceglia; Heidi Sowter; Dennis J Hazelett; Kate Lawrenson; Simon A Gayther Journal: Oncotarget Date: 2017-11-27
Authors: R Manek; E Pakzamir; P Mhawech-Fauceglia; T Pejovic; H Sowter; S A Gayther; K Lawrenson Journal: Oncogenesis Date: 2016-08-15 Impact factor: 7.485